BOOST Pharma receives U.S. FDA Orphan Drug Designation for its innovative therapy to treat Osteogenesis Imperfecta.
May 31, 2022
BOOST Pharma receives U.S. FDA Orphan Drug Designation for its innovative therapy to treat Osteogenesis Imperfecta.
< Back to Updates